Two prices for one product
Open the semaglutide product page and it gives a monthly figure, says everything is included, and says it is billed monthly. Scroll down the same page and its related-products rail gives a starting-from figure for the same drug, a hundred dollars higher. The category page agrees with the rail, not with the product page.
Tirzepatide has the same problem and worse: the starting-from figure is close to double the product-page rate. A starting-from figure that exceeds the plan figure is the wrong way round, which is a sign that one of the two is stale rather than that both describe real options.
We have not chosen between them. Both are stored, each cited to the page it was read on, because a reader who lands on either page will see that page's number.
The third molecule
Liraglutide is priced on the category page. It is a daily rather than a weekly injection, it predates both of the drugs the rest of this market sells, and very few sellers list it at all — so a published figure for it is worth having even though it comes from the page whose other figures are in doubt.
No product page figure for the liraglutide lane appeared, so the category-page figure is the only one there is, and the qualifier says so.
Nobody is named
We read the privacy policy and the terms of use in full, and ran a widened corporate-suffix pattern across every cached page on the host. The only match anywhere is the site's own navigation label. No operating company, no clinical entity, no compounding pharmacy and no individual clinician is named.
The membership question is left open in the same way. The site advertises that it has no hidden membership fees and contrasts itself with a membership fee that hides the real cost of a programme. Neither sentence says whether a membership fee applies here.
Momentum Health's published pricing
| Medication | Price | Verified |
|---|---|---|
| Semaglutide (compounded) | $225/mothe product page figure, printed as "Everything included $225.00 /month Billed monthly" | September 2026source |
| Semaglutide (compounded) | $325/mothe category page figure for the same product, printed as "Starting from $325.00" — a hundred dollars above the product page rate, and repeated in the product page's own cross-sell rail | September 2026source |
| Tirzepatide (compounded) | $275/mothe product page figure, printed as "$275.00 /month Billed monthly" beside a two-month savings note | September 2026source |
| Tirzepatide (compounded) | $499/mothe category page figure for the same product, printed as "Starting from $499.00" — a starting-from figure that is 81% above the product page rate | September 2026source |
| Liraglutide (compounded) | $299/mopublished as "Starting from $299.00" on the category page; no product-page figure for this lane was found | September 2026source |
compareglp may earn a commission when a reader signs up with a provider through a link on this site. 4 of the 198 providers reviewed here are paid partners today; the other 194 are not. See how this works.
See Momentum Health's current price →Good fit if
- Readers looking for a published compounded liraglutide figure, which is rare.
- Buyers who want a figure stated as billed monthly rather than left to inference.
- People comparing three molecules from one seller on one page.
- Anyone who wants to see what happens when a catalogue and a product page fall out of step.
Look elsewhere if
- Readers who need one authoritative price, since the seller publishes two for each drug.
- Anyone who wants to know which company they are contracting with.
- Buyers who need a named compounding pharmacy or a named prescribing clinician.
- Readers who need a service-area list, or for whom an FDA warning letter is disqualifying.
How this review was verified
- Re-read both product pages, the category page, the privacy policy and the terms of use on 7 September 2026, comparing requested to effective URLs and running a nonsense path against the host in the same run, which returned a 404.
- Read the cross-sell rail inside each product page as well as the headline block, which is how the conflicting figure was found on the product page rather than only on the category page.
- Recorded both figures for both drugs rather than picking the one that suited a comparison.
- Ran a widened corporate-suffix pattern, first proved against a page known to name a company, across every cached body on the host; the only match is a navigation label, read in context and rejected.
- Screened the entity form named by the FDA letter and the brand against the live warning-letter datatable with a positive and a negative control in the same invocation, and re-fetched the letter to confirm its title matches the reference number and date.